The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 1087-1096

  Wang, W ^a,b   Slevin, M ^a   Kumar, S ^c   Kumar, P ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

IGF II; Myoblasts; PAX 3 FKHR; Rhabdomyosarcoma; VEGF PDGF B

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, MOUSE; PLATELET DERIVED GROWTH FACTOR B; SOMATOMEDIN B; VASCULOTROPIN A;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE COURSE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; METABOLISM; MITOSIS; MOUSE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TIME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE PROGRESSION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; INSULIN-LIKE GROWTH FACTOR II; MICE; MITOSIS; PAIRED BOX TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-SIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA, ALVEOLAR; TIME FACTORS; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644817251     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.1087     Document Type: Article

References (52)

1. Tiffin N, Williams RD, Shipley J and Pritchard-Jones K: PAX7 expression in embryonal rhabdomyosarcoma suggests origin in muscle satellite cells. Br J Cancer 89: 327-332, 2003.
2. Enzinger FM and Weiss SW: Rhabdomyosarcoma. In: Soft Tissue Tumors. Enzinger FM and Weiss SM (eds). CV. Mosby Co., St. Louis, MO, pp448-488, 1988.
3. Xia SJ, Pressey JG and Barr FG: Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 1: 97-104, 2002.
4. Davis RL, Weintraub H and Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51: 987-1000, 1987.
5. Edmondson DG and Olson EN: A gene with homology to the myc similarity region of MyoDl expressed during myogenesis and is sufficient to activate the muscle differentiation program. Genes Dev 3: 628-649, 1989.
6. Wright WE, Sassoon DA and Lin VK: Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell 56: 607-617, 1989.
7. Braun T, Buschhausen-Denker G, Bober E, Tannich E and Arnold HH: A novel human muscle factor related to but distinct from MyoDl induces myogenic conversion in 10T1/2 fibroblasts. EMBOJ8:701-709, 1989.
8. Rhodes S J and Konieczny SF: Identification of MRF4: a new member of the muscle regulatory factor gene family. Genes Dev 3:2051-2061,1989.
9. Olson EN and Klein WH: bHLH factors in muscle development: deadlines and commitments, what to leave in and what to leave out. Genes Dev 8: 1-8, 1994.
10. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ III, Emanuel BS, Rovera G and Barr FG: Fusion of a forkhead domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5: 230, 1993.
11. Li J and Vogt PK: The retroviral oncogene qin belongs to the transcription factor family that includes the homeotic gene fork head. Proc Natl Acad Sci USA 90: 4490-4494, 1994.
12. Epstein JA, Lam P, Jepeal L, Maas RS and Shapiro DN: Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270: 11719-11722, 1995.
13. Schafer BW, Czerny T, Bernasconi M, Genini M and Busslinger M: Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. Nucleic Acids Res 22: 4574-4582, 1994.
14. Maroto M, Reshef R, Munsterberg AE, Koester S, Goulding M and Lassar AB: Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89: 139-148, 1997.
15. Tajbakhsh S, Rocancourt D, Cossu G and Buckingham M: Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 89: 127-138, 1997.
16. Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzeleck DM, Triche TJ, Bridge JA and Sorensen PH: Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusion. Cancer Res 62: 4704-4710, 2002.
17. Blake J and Ziman MR: Abberant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma? Histol Histopathol 18: 529-539, 2003.
18. Parker CJ, Shawcross SG, Li H, Wang QY, Herrinton S, Kumar S, MacKie RM, Prime W, Rennie IG, Sisley K and Kumar P: Expression of PAX3 alternatively spliced transcripts and identification of two new isoforms in human tumors of neural crest origin. Int J Cancer 108: 314-320, 2004.
19. Fredericks WJ, Galili N, Mudhopadhyay S, Rovera G, Bennicelli J, Barr FG and Rauscher FJ: The PAX3-FKHR fusion protein created by the t (2/13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15: 1522-1535, 1995.
20. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ and Barr FG: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20: 2672-2679, 2002.
21. Wang W, Kumar P, Wang WZ, Epstein J, Helman L, Moore J and Kumar S: IGF-1I and PAX3-FKHR co-operate in the oncogenesis of rhabdomyosarcoma. Cancer Res 58: 4426-4433, 1998.
22. Lagutina I, Conway SJ, Sublett J and Grosveld GC: Pax-3- FKHR knock-in mice show developmental aberrations but do not develop tumours. Mol Cell Biol 20: 7204-7216, 2002.
23. Barber TD, Barber MC, Tomescu O, Barr FG, Ruben S and Freidman TB: Identification of target regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics 79: 278-284, 2002.
24. Tomescu O, Xia SJ, Strezlecki D, Bennicelli JL, Ginsberg J, Pawal B and Barr FG: Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab Invest 84: 1060-1070, 2004.
25. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 65: 311-320, 1992.
26. Florini JR, Ewton DZ, Falen S and van Wyk JJ: Biphasic concentration dependency of stimulation of myoblast differentiation by somatomedins. Am J Physiol 250: C771-C778, 1986.
27. Minniti CP, Luan D, O'Grady C, Rosenfeld RG and Helman LJ: Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ 6: 263-269, 1995.
28. Harrington EA, Bennett MR, Fanidi A and Evan GI: c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13: 3286-3295, 1994.
29. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
30. Wagner M and Perry RP: Characterisation of the gene encoding the mouse ribosomal protein: strategy for distinguishing an expressed gene fropm its processed pseudogene counterparts by an analysis of total genomic DNA. Mol Cell Biol 5: 3560-3576, 1985.
31. Eilers M, Schirm S and Bishop JM: The Myc protein activates transcription of the alpha prothymosin gene. EMBO J 10: 133-141, 1991.
32. Evan H, Wyllie A, Gilbert C, Littlewood T, Land H, Brooks M, Waters C, Penn L and Hancock D: Induction of apoptosis in fibroblasts by c-myc protein. Cell 63: 119-125, 1992.
33. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH and Helman LJ: Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1: 325-331, 1990.
34. Davis RJ and Barr FG: Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA 94: 8047-8051, 1997.
35. Anderson J, Ramsay A, Gould S and Pritchard-Jones K: PAX3- FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 159:1089-1096,2001.
36. Spizz G, Roman D, Strauss A and Olson EN: Serum and fibroblast growth factor inhibit myogenic differentiation through a mechanism dependent on protein synthesis and independent of cell proliferation. J Biol Chem 261: 9483-9488, 1986.
37. Rudnicki MA, Braun T, Hinuma S and Jaenisch R: Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell 71: 383-390, 1992.
38. Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH and Jaenisch R: MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 75: 1351-1359, 1993.
39. Peterson CA, Gordon H, Hall ZW, Paterson BM and Blau HM: Negative control of the helix-loop-helix family of myogenic regulators in the NFB mutant. Cell 62: 493-502, 1990.
40. Brennan MF: Management of extremity soft tissue sarcoma. Miles Lecture. Eur J Surg Oncol 16: 520-531, 1990.
41. Bengal E, Ransone L, Scharfmann R, Dwarki VJ, Tapscott SJ, Weintraub H and Verma IM: Functional antagonism between c-jun and MyoD proteins: a direct physical association. Cell 68: 507-519,1992.
42. Tonin PN, Scrable H, Shimada H and Cavenee WK: Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 51: 5100-5106,1991.
43. Tapscott SJ, Thayer MJ and Weintraub H: Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 259: 1450-1453, 1993.
44. Chen B, Dias P, Jenkins JJ III, Saveli VH and Parham DM: Methylation alterations of the MyoDl upstream region are predictive of sub-classification of human rhabdomyosarcomas. AmJ Pathol 152: 1071-1079, 1998.
45. Jin P, Farmer K, Ringertz NR and Sejersen T: Proliferation and differentiation of human fetal myoblasts is regulated by PDGF-BB. Differentiation 54: 47-54, 1993.
46. Christofori G, Naik P and Hanahan D: A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414-417, 1994. et al.
47. Epstein JA, Song B, Lakkis M and Wang C: Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 18: 4118-4130,1998.
48. Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R, Murray MJ and Bowen-Pope DF: Two classes of PDGF receptor recognize different isoforms of PDGF. Science 240: 1529-1531, 1988.
49. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
50. Shibuya M: Role of VEGF-FLT receptor system in normal and tumour angiogenesis. Adv Cancer Res 68: 281-316, 1996.
51. Akagi Y, Liu W, Zebrowski B, Xie K and Ellis ML: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58: 4008-4014, 1998.
52. Folkman J: What is the evidence that tumors are angiogenesisdependent? J Natl Cancer Inst 82: 4-6, 1991.